A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma

References

• Rajkumar SV . Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am. J. Hematol.95(5), 548–567 (2020).
   PubMed Web of Science ®Google Scholar
• Chari A , VoglDT, GavriatopoulouMet al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N. Engl. J. Med.381(8), 727–738 (2019).
   PubMed Web of Science ®Google Scholar
• Lonial S , LeeHC, BadrosAet al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label phase 2 study. Lancet Oncol.21(2), 207–221 (2020).
   PubMed Web of Science ®Google Scholar
• Bruno AS , WillsonJL, OpalinskaJMet al. Recent real-world treatment patterns and outcomes in US patients with relapsed/refractory multiple myeloma. Expert Rev. Hematol.13(9), 1017–1025 (2020).
   PubMed Web of Science ®Google Scholar
• American Cancer Society . Drug therapy for multiple myeloma (2021). www.cancer.org/cancer/multiple-myeloma/treating/chemotherapy.html
   Google Scholar
• Nijhof IS , GroenRW, NoortWAet al. Preclinical evidence for the therapeutic potential of CD38-targeted immuno-chemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin. Cancer Res.21(12), 2802–2810 (2015).
   PubMed Web of Science ®Google Scholar
• Ocio EM , VilanovaD, AtadjaPet al. In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma. Haematologica95(5), 794–803 (2010).
   PubMed Web of Science ®Google Scholar
• Giliberto M , ThimiriGovinda Raj DB, CremaschiAet al. Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically. Mol. Oncol.16(6), 1241–1258 (2022).
   PubMed Web of Science ®Google Scholar
• Liu J , WangL, ZhaoFet al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLOS ONE10(9), e0137345 (2015).
   PubMed Web of Science ®Google Scholar
• Chao MP , TakimotoCH, FengDDet al. Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies. Front. Oncol.9, 1380 (2020).
   PubMed Web of Science ®Google Scholar
• Chao MP , JaiswalS, Weissman-TsukamotoRet al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci. Transl. Med.2(63), 63ra94 (2010).
   PubMed Web of Science ®Google Scholar
• Kim D , WangJ, WillinghamSB, MartinR, WernigG, WeissmanIL. Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia26(12), 2538–2545 (2012).
   PubMed Web of Science ®Google Scholar
• Sun J , MuzB, AlhallakKet al. Targeting CD47 as a novel immunotherapy for multiple myeloma. Cancers (Basel)12(2), 305 (2020).
   PubMed Web of Science ®Google Scholar
• Soto-Pantoja DR , TerabeM, GhoshAet al. CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res.74(23), 6771–6783 (2014).
   PubMed Web of Science ®Google Scholar
• Liu X , PuY, CronKet al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med.21(10), 1209–1215 (2015).
   PubMed Web of Science ®Google Scholar
• Schwartz AL , NathPR, AllgauerMet al. Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation. Cancer Immunol. Immunother.68(11), 1805–1817 (2019).
   PubMed Web of Science ®Google Scholar
• Hendriks M , BritschI, KeXet al. Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axis. Oncoimmunology10(1), 2005344 (2021).
   PubMed Web of Science ®Google Scholar
• Chao MP , MajetiR, WeissmanIL. Programmed cell removal: a new obstacle in the road to developing cancer. Nat. Rev. Cancer12(1), 58–67 (2012).
   Web of Science ®Google Scholar
• Daver NG , VyasP, KambhampatiSet al. Tolerability and efficacy of the first-in-class anti-C47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia: phase 1b results. J. Clin. Oncol.40(Suppl. 16), Abstract 7020 (2022).
   Web of Science ®Google Scholar
• Sallman DA , AlMalki M, AschASet al. Magrolimab in combination with azacitidine for untreated higher risk myelodysplastic syndrone (HR-MDS): 5F9005 phase 1b study results. J. Clin. Oncol.40(Suppl. 16), Abstract 7017 (2022).
   Web of Science ®Google Scholar
• ClinicalTrials.gov . Study of magrolimab in participants with solid tumors (2022). https://clinicaltrials.gov/ct2/show/NCT04827576
   Google Scholar
• Darzalex Faspro (daratumumab and hyaluronidase-fihj) . Prescribing information.Janssen Biotech, Inc. 1-16 Horsham, PA, USA (2022).
   Google Scholar
• Darzalex (daratumumab) . Prescribing information.Janssen Biotech, Inc. 1-16Horsham, PA, USA (2022).
   Google Scholar
• Mahaweni NM , BosGMJ, MitsiadesCS, TilanusMGJ, WietenL. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions. Cancer Immunol. Immunother.67(6), 861–872 (2018).
   PubMed Web of Science ®Google Scholar
• Cho H , KimKH, LeeHet al. Adaptive natural killer cells facilitate effector functions of daratumumab in multiple myeloma. Clin. Cancer Res.27(10), 2947–2958 (2021).
   PubMed Web of Science ®Google Scholar
• Krejcik J , CasneufT, NijhofISet al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood128(3), 384–394 (2016).
   PubMed Web of Science ®Google Scholar
• Advani R , FlinnI, PopplewellLet al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N. Engl. J. Med.379(18), 1711–1721 (2018).
   PubMed Web of Science ®Google Scholar
• Pomalyst (pomalidomide) . Prescribing information.Celgene Corporation. 1-16Summit, NJ, USA (2021).
   Google Scholar
• Revlimid (lenalidomide) . Prescribing information.Celgene Corporation.1-28Princeton, NJ, USA (2022).
   Google Scholar
• Mitsiades N , MitsiadesCS, PoulakiVet al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood99, 4525–4530 (2002).
   PubMed Web of Science ®Google Scholar
• Hideshima T , ChauhanD, ShimaYet al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood96, 2943–2950 (2000).
   PubMed Web of Science ®Google Scholar
• Pierceall WE , AmatangeloMD, BahlisNJet al. Immunomodulation in pomalidomide, dexamethasone, and daratumumab-treated patients with relapsed/refractory multiple myeloma. Clin. Cancer Res.26(22), 5895–5902 (2020).
   PubMed Web of Science ®Google Scholar
• Kyprolis (carfilzomib) . Prescribing information.Onyx Pharmaceuticals; Amgen Inc. 1-85Thousand Oaks, CA, USA (2022).
   Google Scholar
• Velcade (bortezomib). Prescribing information.Takeda Pharmaceuticals America Inc. 1-44Lexington, MA, USA (2021).
   Google Scholar
• Kuhn DJ , ChenQ, VoorheesPMet al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood110(9), 3281–3290 (2007).
   PubMed Web of Science ®Google Scholar
• Boccadoro M , MorganG, CavenaghJ. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int.5(1), 18 (2005).
   PubMed Web of Science ®Google Scholar
• Richards J , BouchlakaMN, PuroRJet al. Highly differentiated anti-CD47 antibody, AO-176, potently inhibits hematologic malignancies alone and in combination. Blood134(Suppl. 1), 1844 (2019).
   Google Scholar
• Linderoth E , HelkeS, LeeVet al. The anti-myeloma activity of TTI-621 (SIRPαFc), a CD47-blocking immunotherapeutic, is enhanced when combined with a proteasome inhibitor. Presented at: AACR Annual Meeting 2017.Washington, DC, USA (1–5 April 2017).
   Google Scholar
• Swoboda DM , SallmanDA. The promise of macrophage directed checkpoint inhibitors in myeloid malignancies. Best Pract. Res. Clin. Haematol.33(4), 101221 (2020).
   PubMed Web of Science ®Google Scholar
• Gandhi UH , CornellRF, LakshmanAet al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia33(9), 2266–2275 (2019).
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov . Study of magrolimab combinations in participants with relapsed/refractory multiple myeloma (2022). https://clinicaltrials.gov/ct2/show/NCT04892446
   Google Scholar